Poster Sessions

from powder diffraction data.
Glyceryl-<i>L</i>-tyrosine is known to crystallize as dihydrate from an aqueous-methanol solution [1]. Recently, we obtained the trihydrate from an aqueous solution, and carried out single-crystal structure analysis [2]. Humidity- and temperature-dependent phase transitions of both hydrates were examined by powder X-ray diffraction analysis. The dihydrate is stable at room temperature in the relative humidity (rh) range from 80% to 0% and the structural transition proceeds around 50 °C at 0% rh. On the other hand, the trihydrate loses a part of crystal water at 0% rh, and further dehydrates around 80 °C.

At the first step, we have successfully determined the crystal structure of the dihydrate from powder diffraction data. The structure coincides with that determined by single-crystal structure analysis. In addition the cell parameters of the partly dehydrated state of the trihydrate at 0% rh have been determined and structure analysis from powder diffraction data is in progress.

---

**MS10.P09**


**Powder structures of two pharmaceutically interesting alkylaminobisphosphonates**

Manu Lahtinen, Petri Turhanen, Ainu Saari, Jouko Vepsäläinen, Department of Chemistry, University of Jyväskylä, P.O.Box 35, FI-40014 Jyväskylä, Finland.

Alkylaminobisphosphonates are widely utilized by industry as detergents, corrosion inhibitors and tartar preventer in tooth paste. More recently their therapeutic properties were discovered in form of ability to inhibit bone resorption, thereby enabling their use for treating various bone diseases (osteoporosis, skeletal metastases from solid tumours, hypercalcaemia of malignancy, multiple myeloma and Paget’s disease). Bisphosphonates are widely studied (mostly in health-related aspects), as nearly 6000 articles have appeared since year 2000 alone, of which only around 50 deals with their structural chemistry. Therefore in this study, <i>ab initio</i> powder structure determination of two switertionic, alkylamino-bisphosphonates having amino group in the b position of the carbon chain, will be presented and compared with the existing crystal structures found in the literature. The presented compounds were synthesized according to the method reported by Kieczykowski et al.²

---

**MS10.P08**


**Ab-initio Structure determination of a new phosphodiesterase enzyme inhibitor**

Ali Reza Salimi, Hossein Eshtiag-Hosseini, Hamid Sadeghian, Fabia Gozzo, Mostafa Mohammadpour Amini, Hamid Reza Khavasi, Department of Chemistry, Ferdowsi University of Mashhad, Mashhad 917791436, Iran.

Crystal Structural change by guest sorption/release processes of the macrocyclic boronic ester

Kotaro Fujii, Hidehiro Uekusa, Yuji Kikuchi, Hiroki Takahagi, Kosuke Ono, Nobuharu Iwasawa, Department of Chemistry and Materials Science, Tokyo Institute of Technology, Japan.

Macroyclic compounds attract many interest because they can be used as a host molecule to absorb and store several types of guest molecules. Recently, diboronic acid and racemic tetrol [1] are found to form a self-assembled macrocyclic boronic ester in the presence of appropriate guest molecules. Among this type of compounds, the toluene inclusion crystal of the macrocyclic boronic ester [2] was found to form one dimensional stacking of along the b-axis with an infinite one dimensional toluene tunnel structure. It is interesting to explore the crystal structure of the guest-free aphphost, in order to investigate whether the crystal can retain its one dimensional tunnel structure, which has enough size to absorb guest molecules, after the guest release. However, 2 tends to incorporate guest molecules during the recrystallization processes and the aphphost crystal can only be obtained by guest release process, such as heating of the sample, which usually results to form micro-crystalline powders. Obviously, the crystal structure determination from powder X-ray diffraction data is an essential tool to establish the crystal structure of the aphphost. In this study, we focused on structure determination of 6-(4-(4-(4-methylpiperazin-1-yl)-4-oxobutoxy)-4-methylquinolin-2(1H)-one as a phosphodiesterase (PDE) enzymes inhibitor which improve cardiac contractility and may be used in congestive heart failure (CHF) which is a major cause of death in patients with heart disease [2].

---

**Keywords:** Glyceryl-L-tyrosine, powder diffraction, dihydrate

**Keywords:** Glycyl-L-Tyr, powder diffraction, hydrate

**Keywords:** Synchrotron, Powder Diffraction, Enzyme Inhibitor

---


**Keywords:** alkylaminobisphosphonates, X-ray powder diffraction, pharmaceutical

---

**Keywords:** alkylaminobisphosphonates, X-ray powder diffraction, pharmaceutical